Weiler Kathy Johnson sold $641K of AXGN
Weiler Kathy Johnson sold 14,150 shares of Axogen, Inc. (AXGN) at $45.30 ($0.64M total) on 2026-08-07 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the disclosed sale size, price, and that it was executed under a Rule 10b5-1 plan; no new company fundamentals are provided.
Market read
Traders may briefly reassess sentiment around AXGN due to the director’s sale, but the 10b5-1 framing reduces interpretive weight.
What to watch
The article does not provide context on total holdings before/after beyond “0 shares,” nor does it indicate whether other insiders sold or whether there were concurrent company catalysts.
Background
The article is a SEC Form 4 insider transaction disclosure for Axogen, Inc. (AXGN).
Ticker impact
Axogen director Weiler Kathy Johnson filed a Form 4 selling 14,150 shares at $45.2980 on 2026-08-07 under a 10b5-1 plan.
Low likelihood of sustained price impact; any reaction is likely limited to sentiment and positioning.
The filing is a routine 10b5-1 open-market sale with no accompanying operational, financial, or regulatory change disclosed in the text.
Market effects
No clear sector read-through from a single routine 10b5-1 insider sale.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.
Key entities
- issuerAxogen, Inc.
Company whose director insider sale is disclosed via Form 4.
- insiderWeiler Kathy Johnson
Director who sold 14,150 shares in an open-market transaction under a 10b5-1 plan.
